Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells

Qinghaosu (artemisinin): Chemistry and pharmacology

(2012) Ying Li   ACTA PHARMACOLOGICA SINICA

Artemisinin-Resistant Malaria: Research Challenges, Opportunities, and Public Health Implications

(2012) Rick M. Fairhurst et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo

(2012) Chris Zhiyi Zhang et al.   BIOCHEMICAL PHARMACOLOGY

Curcumin inhibits protein phosphatases 2A and 5, leading to activation of mitogen-activated protein kinases and death in tumor cells

(2012) Xiuzhen Han et al.   CARCINOGENESIS

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Dihydroartemisinin Ameliorates Inflammatory Disease by Its Reciprocal Effects on Th and Regulatory T Cell Function via Modulating the Mammalian Target of Rapamycin Pathway

(2012) Yan G. Zhao et al.   JOURNAL OF IMMUNOLOGY

Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) soft-tissue Sarcoma committee experience and rationale for current COG studies

(2012) Suman Malempati et al.   PEDIATRIC BLOOD & CANCER

Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo

(2011) Ning Gao et al.   APOPTOSIS

Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway

(2011) Shuang-Jia Wang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1

(2011) Paige Yellen et al.   CELL CYCLE

Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells

(2010) Jin-Jian Lu et al.   BIOCHEMICAL PHARMACOLOGY

Dihydroartemisinin inactivates NF-κB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo

(2010) Shuang-Jia Wang et al.   CANCER LETTERS

The antitumor activity of the fungicide ciclopirox

(2010) Hongyu Zhou et al.   INTERNATIONAL JOURNAL OF CANCER

Rapamycin Inhibits Cytoskeleton Reorganization and Cell Motility by Suppressing RhoA Expression and Activity

(2010) Lei Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

mTOR signaling and drug development in cancer

(2010) Janet Dancey   Nature Reviews Clinical Oncology

Rapamycin Inhibits IGF-1 Stimulated Cell Motility through PP2A Pathway

(2010) Lei Liu et al.   PLoS One

mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs

(2010) R. J. O. Dowling et al.   SCIENCE

Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005

(2009) Simona Ognjanovic et al.   CANCER

Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro

(2009) Hui-Jun Zhou et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

(2009) Timothy R. Peterson et al.   CELL

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

(2008) Juan M. García-Martínez et al.   BIOCHEMICAL JOURNAL

Transcriptional control of human p53-regulated genes

(2008) Todd Riley et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins

(2008) L Liu et al.   ONCOGENE